Progress in molecularly targeted therapies for acute myeloid leukemia

DOI Web Site PubMed
  • TOMITA Akihiro
    Department of Hematology and Oncology, Nagoya University Graduate School of Medicine

Bibliographic Information

Other Title
  • 急性骨髄性白血病に対する分子標的療法の進歩
  • キュウセイ コツズイセイ ハッケツビョウ ニ タイスル ブンシ ヒョウテキ リョウホウ ノ シンポ

Search this article

Abstract

Genetic abnormalities including specific point mutations have recently been confirmed by applying comprehensive genome sequencing analyses. Molecular targeting therapies, which focus on the mutated proteins and over-expressed proteins in acute myeloid leukemia (AML) cells, are now being developed in clinical studies and/or based on in vitro analyses. This manuscript summarizes the genetic abnormalities in AML cells and some of the current molecular targeting therapies including FLT3 inhibitors (e.g. AC220; Quizartinib), Polo like kinase 1 (PLK1) inhibitors (e.g. BI-6727; Volasertib), IDH2 inhibitors (e.g. AG-221), and XPO1 inhibitors (e.g. KPT-330; Selinexor).

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 56 (2), 130-138, 2015

    The Japanese Society of Hematology

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top